Business Wire

CA-YUGABYTE

3.3.2021 15:02:14 CET | Business Wire | Press release

Share
Yugabyte Raises $48 Million Funding Round to Accelerate Distributed SQL Enterprise Adoption and Fuel Global Expansion

Yugabyte , the leader in open source distributed SQL databases, today announced a $48 million funding round led by Lightspeed Venture Partners with additional participation by Greenspring Associates, Dell Technologies Capital, Wipro Ventures and 8VC. Coming on the heels of a $30 million capital raise announced in June 2020, the round brings Yugabyte’s total funding to $103 million. The funding will be used to expand Yugabyte’s R&D, sales and customer functions in the EMEA and APAC markets. To support its aggressive expansion plans, Yugabyte will double its headcount in 2021.

With the new infusion of capital, Yugabyte is building out its engineering, DevOps and support staff in India, Russia and Canada. To turbo-charge these efforts, it recently acquired India-based Falarica.io to accelerate its development and recruiting efforts in the APAC region. The company is also expanding its sales teams in EMEA and APAC because of strong demand for its open source distributed SQL database, and related products and services.

Enterprise adoption of YugabyteDB continues to accelerate, particularly in the e-commerce, financial services and telecommunications verticals where geographic data distribution, transactional capabilities and horizontal scalability are critical for systems of record. Yugabyte customers include Hudson River Trading, Kroger, Narvar, Turvo, Manetu and Xignite, among others.

“Today’s business environment demands flexibility and elasticity from database solutions, and distributed SQL is now critical for any organization where developer productivity and application uptime are top priorities. YugabyteDB makes something as fundamental and feature rich as PostgreSQL truly cloud native, resilient, elastic, and distributed,” said Kannan Muthukkaruppan, Co-Founder and President, Yugabyte. “With companies of all kinds accelerating their digital transformation initiatives, technologies that help them accelerate, like YugabyteDB, are in high demand. This new round of funding will position Yugabyte to meet this increased enterprise demand and power our global expansion into key markets.”

Over the past year, organizations have transitioned more work and non-work activities to the cloud, increasing the demand for cloud-native relational database management systems to ensure data is always available and can be accessed at the lowest possible latency. Enterprises and startups in need of increased flexibility turn to YugabyteDB for its PostgreSQL-compatibility and out-of-the-box support for multi-cloud deployments, enabling them to experience the full benefits of true cloud elasticity.

“Several different trends are intersecting in the enterprise—the exponential growth of data, the acceleration of digital transformation, and the move to cloud—forcing organizations to rethink how they manage their data and creating an opportunity for organizations like Yugabyte,” said Ravi Mhatre, Partner at Lightspeed Venture Partners. “With its unique combination of advanced RDBMS features, high availability, horizontal scalability, and ability to distribute data anywhere in the world, YugabyteDB is already the beating heart of many mission-critical global applications and will soon underpin many more. We're excited for this next stage of the company's growth.”

The funding will also be used to further accelerate enterprise adoption of Yugabyte’s commercial products. Yugabyte Platform , a self-managed private database-as-a-service offering available on any public, private, or hybrid cloud or Kubernetes infrastructure and Yugabyte Cloud , a fully-managed database service currently available on AWS and Google Cloud, have seen broad adoption in the past 12 months. Yugabyte also recently announced YugabyteDB 2.4 , a major update including hardened enterprise-grade security features, enhanced multi-region deployment capabilities and significant performance improvements.

Yugabyte is true open source with its permissive Apache 2.0 license, a position that has helped win customers and drive strong open source community growth. Yugabyte’s open source community members have now deployed more 600,000 clusters to-date and the project’s contributor count is now over 170, with +2,600 community Slack members and over 300 certifications granted in the last 90 days.

For more information, visit www.yugabyte.com or check out the company blog: https://blog.yugabyte.com/yugabyte-secures-48m-in-funding/ .

About Yugabyte

Yugabyte is the company behind YugabyteDB, the open source, high-performance distributed SQL database for building global, internet-scale applications. YugabyteDB serves business-critical applications with SQL query flexibility, high performance and cloud native agility, thus allowing enterprises to focus on business growth instead of complex data infrastructure management. It is trusted by companies in cybersecurity, financial markets, IoT, retail, e-commerce, and other verticals. Founded in 2016 by former Facebook and Oracle engineers, Yugabyte was named a 2020 Cool Vendor by Gartner and is backed by 8VC, Wipro Ventures, Greenspring Associates, Lightspeed Venture Partners and Dell Technologies Capital. www.yugabyte.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye